Malaria: Still no vaccine and very few drugs

Current Opinion in Infectious Diseases

Volumn 9, Issue 6, 1996, Pages 429-434

  Nosten, François ^a,c   Van Vugt, Michèle ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c SHOKLO MALARIA RESEARCH UNIT   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEETHER; ARTEMISININ DERIVATIVE; ATOVAQUONE; AZITHROMYCIN; CHLOROQUINE; FANSIDAR; HALOFANTRINE; MALARIA VACCINE; MEFLOQUINE; PRIMAQUINE; PROGUANIL; PYRONARIDINE; QUININE;

CARDIOTOXICITY; DRUG RESISTANCE; MALARIA; PLASMODIUM FALCIPARUM; SHORT SURVEY; VOMITING;

EID: 0030471441     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199612000-00015     Document Type: Short Survey

References (52)

1. Alonso PL, Smith T, Armstrong-Scellenberger JRM, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C et al.: Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994, 344:1175-1181.
2. D'Alessandro U, Leach A, Drakeley CJ, Bennett S, Olaleye BO, Fegan GW, Jawara M, Langerock P, George MO, Targett GAT, Greenwood BM: Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995, 346:462-467.
3. Nosten F, Luxemburger C, Kyle D, Ballou WP, Wittes J, Eh WAH, Chongsuphajaisiddhi T, Gordon DM, White NJ, Sadoff JC, Heppner DG: Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in Northwestern Thailand. Lancet 1996, 348:701-707. This paper describes the first trial of SPf66 in Asia. This is the most detailed evaluation ever conducted with a malaria vaccine and concludes that SPf66 is not protective against P. falciparum.
4. Gordon DM, McGovern TW, Krzych U, Cohen JC, Scheider I, Lachance R, Heppner DG, Yuan G, Hollingdale M, Hauser P et al.: Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein hepatitis B surface antigen subunit vaccine. J Infect Dis 1995, 171:1576-1585
5. Barennes H, Kahiatani F, Pussard E, Clavier F, Meynard D, Njifountawouo S, Verdier F: Intrarectal Quinimax (an association of cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. Trans R Soc Trop Med Hyg 1995, 89:418-421 The rectal route was compared with the intramuscular route. The efficacy was satisfactory although the bioavailability of the drug was lower than with the intramuscular injection. This route of administration could prove useful in situations where basic healthcare is lacking, and to reduce the risk of cross infections through contaminated needles.
6. Kremsner PG, Radloff P, Metzger W, Widling E, Mordmuller B, Phillips J, Jenne L, Nkeyi M, Prada J, Bienzle U, Graninger W: Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob Agents Chemother 1995, 39:1603-1605.
7. Deloron P, Aubry P, Ndayirabije A, Clavier F, Verdier F: Pefloxacin does not potentiate quinine efficacy against Plasmodium falciparum malaria. Am J Trop Med Hyg 1995, 53:646-647.
8. Mapaba E, Hellgren U, Landberg-Lindgren A, Rombo L: Susceptibility of Plasmodium falciparum to quinine in vitro: effects of drug concentrations and time of exposure. Trans R Soc Trop Med Hyg 1995, 89:85-89.
9. Gasquet M, Delmont J, Lebras J, Delmas F, Capdegelle P, Timondavid P: Chloroquine-resistant falciparum malaria in Mauritania [Letter]. Lancet 1995, 346:1556.
10. Adagu IS, Warhurst DC, Ogala NW, Abdu-Aguye I, Bamgbola FO, Ovwigho UB: Antimalarial drug response of Plasmodium falciparum from Zaria, Nigeria. Trans R Soc Trop Med Hyg 1995, 89:422-425.
11. Benito A, Roche J, Molina R, Amela C, Alvar J: In-vitro susceptibility of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine and sulphadoxine pyrimethamine in Equatorial Guinea. Am J Trop Med Hyg 1995, 53:526-531.
12. Brasseur P, Agnamey P, Same Ekobo A, Samba G, Favennec L, Kouamouo J: Sensitivity of Plasmodium falciparum to amodiaquine and chloroquine in central Africa: a comparative study in vivo and in vitro. Trans R Soc Trop Med Hyg 1995, 89: 528-530. This trial was conducted in 1991-1992 in Cameroon and the Congo. Amodiaquine had a cure rate by day 7 of 80% compared with 60% for chloroquine. Fifty per cent of the strains were resistant in vitro to chloroquine and 9% were resistant to amodiaquine. The investigators strongly suggest that amodiaquine should be used as a first-line treatment of uncomplicated malaria in chloroquine-resistant areas of Africa.
13. Wolday D, Kibreab T, Bukenya D, Hodes R: Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire. Trans R Soc Trop Med Hyg 1995, 89:654-656. The authors report a difference in baseline parasitaemia and in cure rate between malnourished and well-nourished patients. The latter may be caused by a difference in drug absorption and the difference in parasitaemia may have been confounded by age.
14. Cot M, Lehesran JY, Miailhes P, Esveld M, Etyaale D, Breart G: Increase of birth weight following chloroquine chemoprophylaxis during the first pregnancy: results of a randomized trial in Cameroon. Am J Trop Med Hyg 1995, 53:581-585. The mean birthweight was increased by 207 g in the treated group. Such a large effect of prophylaxis on birthweight is unusual and difficult to reconcile with the modest reduction in placental parasitaemia observed in this study.
15. Metzger W, Mordmuller B, Graninger W, Bienzle U, Kremsner PG: Sulfadoxine/pyrimethamine or chloroquine clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. J Antimicrob Chemother 1995, 36:723-728 This open randomized trial compares high dose chloroquine (alone or with clindamycine) with Fansidar in Gabon. Failure rate was 32% in the chloroquine group but the rate of high grade failure was reduced to 7%. The chloroquine plus clindamycine achieved 94% cure rate and SP 98%.
16. Liu DQ, Liu RJ, Ren DX, Gao DQ, Zhang CY, Qiu CP, Cai XZ, Ling CF, Song AH, Tang X: Changes in the resistance of Plasmodium falciparum to chloroquine in Hainan, China. J Antimicrob Chemother 1995, 73:483-486.
17. Wernsdorfer WH, Landgraf B, Weidermann G, Kollaritsch H: Chloroquine resistance of Plasmodium falciparum: a biological advantage? Trans R Soc Trop Med Hyg 1995, 89:90-91.
18. Soto J, Martinez R, Fonschiffrey G, Dember J: Efficacy of Fansidar for acute uncomplicated malaria due to Plasmodium falciparum in Colombia. Trans Roy Soc Trap Med Hyg 1996, 89:306.
19. Plowe CV, Djimde A, Doumbo O, Wellems TE: Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 1995, 52:565-568.
20. Price RN, Nosten F, Luxemburger C, Am Kham, Brockman A, Chongsuphajaisiddhi T, White NJ: Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg 1995, 89:523-527. This is the first comparative trial of artemether and artesunate. Both were equally effective in combination with mefloquine. No side effect attributable to the artemisinin derivatives was detected.
21. Mockenhaupt FP: Mefloquine resistance in Plasmodium falciparum. Parasitol Today 1995, 11:248-253. An extensive review of mefloquine resistance. The paper includes an analysis of the factors that influence the development of mefloquine resistance, the possible underlying mechanism and the geographical spread.
22. Sowunmi A, Oduola AM: Open comparison of mefloquine, mefloquine/sulfadoxine/pyrimethamine and chlorquine in acute uncomplicated falciparum malaria in children. Trans R Soc Trop Med Hyg 1995, 89:303-305.
23. Ter Kuile F, Nosten F, Luxemburger C, Kyle D, Teja Isavadharm P, Phaipun L, Price RN, Chongsuphajaisiddhi T, White NJ: Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull WHO 1995, 73:631-642. A meta-analysis of adverse effects following mefloquine treatment. The large number of patients and the detailed follow up allow a good analysis of the risk factors associated with the side effects.
24. Ter Kuile F, Luxemburger C, Nosten F, Kyaw Lay Thwai, Chongsuphajaisiddhi T, White N: Predictors of mefloquine treatment failure: a prospective study in 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1995, 89:660-664. This analysis provides useful and practical information on the risks associated with treatment failure after mefloquine treatment.
25. Luxemburger C, Price RN, Nosten F, Ter Kuile F, Chongsuphajaisiddhi T, White NJ: Mefloquine in infants and young children. Ann Trop Paediatr 1996 (in press). This meta-analysis of mefloquine treatment in children under 5 years of age shows that the major problem in giving mefloquine to young children is early vomiting. This can be reduced by previous treatment of the fever and by initiating the treatment with artesunate.
26. Matson PA, Luby SP, Redd SC, Roka HR, Menwether RA: Cardiac effects of standard-dose halofantrine therapy. Am J Trop Med Hyg 1996, 54:229-231.
27. Touze JE, Bernard J, Keundjia A, Imbert P, Viguier A, Chaudet H, Doury JC: Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. Am J Trop Med Hyg 1996, 54:225-228.
28. Monlun E, Le Metayer P, Szwandt S, Neau D, Longy-Boursier M, Horton J: Cardiac complications of halofantrine: a prospective study of 20 patients. Trans R Soc Trop Med Hyg 1995, 89:430-433.
29. Sowunmi A, Oduola AM, Salako LA: Artemether treatment of sulfadoxine/pyrimethamine-resistant Plasmodium falciparum malaria in children. Trans R Soc Trop Med Hyg 1995, 89:435-436.
30. Hassan Alin M, Kihamia CM, Björkman A, Bwijio BA, Premji Z, Mtey GJB, Ashton M: Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum and in-vitro susceptibility to artemisinin, chloroquine, and mefloquine. Am J Trop Med Hyg 1995, 53:639-645.
31. World Health Organization: The role of artemisinin and its derivatives in the current treatment of malaria. Report on an informal consultation convened in Geneva, 27-29 September 1993. World Health Organization, mimeograph document WHO/MAIL 94.1067
32. Price RN, Nosten F, Luxemburger C, Ter Kuile F, Phaipun L, Chongsuphajaisiddhi T, White NJ: Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996, 347:1654-1658. This analysis on a large number of observations (over 3600) suggests for the first time that the artemisinin derivaties could be used to slow the spread of resistant strains.
33. Carmen Duarte E, Fernandes Fontes J, Gyorkos TW, Abrahamowicz M: Randomized controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated Plasmodium falciparum malaria in Brazil. Am J Trop Med Hyg 1996, 54:197-202.
34. Murphy S, Watkins WM, Bray PG, Lowe B, Winstanley PA, Peshu N, Marsh K: Parasite viability during treatment of severe falciparum malaria: differential effects of arthemeter and quinine. Am J Trop Med Hyg 1995, 53:303-305.
35. Luxemburger C, Nosten F, Shortar, Raimond D, Chongsuphajaisiddhi T, White NJ: Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria. Am J Trop Med Hyg 1995, 53:522-525. This randomized trial describes the effectiveness of oral artesunate in the treatment of hyperparasitaemic patients along the Thai-Burmese border. The differences compared with intravenous quinine in terms of parasite and fever clearance, cost and duration of hospitalization were among the largest observed.
36. •], this is the largest trial on severe malaria ever conducted. There was no difference in mortality or residual neurological sequelae between the two groups. Time to coma recovery was longer in the artemether group (26 h versus 20 h; P = 0.046). Parasite clearance time was shorter in the artemether group: 48 h versus 60 h. More children in the artemether group had convulsions: odds ratio = 1.86 (1.28-2.71).
37. Hien TT, Day NPJ, Phu NH, Mai NT, Chau TT, Loc PP, Sinh DX, Chuong LV, Vinh H, Waller D et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996, 335:76-83. A randomized double-blind trial in 560 adults with severe artemether malaria. There was no difference in mortality, but a more rapid paracite clearance time in the artemether group: 72 versus 90 h, a slower fever clearance time: 127 versus 90 h and a longer time to coma resolution: 66 versus 48 h, and a longer hospitalization: 288 versus 240 h. More patients in the quinine groups developed hypoglycaemia.
38. Brewer TG: Fatal neurotoxicity due to arteether and artemether. Am J Trop Med Hyg 1992, 47:251-259.
39. Baird JK, Fryauff DJ, Basri H, Bangs MJ, Subianto B, Wiady I, Purnomo, Lekasana B, Masbar S, Richie TL et al.: Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 1995, 52:479-484.
40. Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL: Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 1995, 171:1569-1575.
41. Shanks DG, Barnett A, Edstein M, Rieckmann KH: Effectiveness of doxycycline combined with primaquine for malaria prophylaxis. Med J Aust 1995, 162:306-310.
42. Basco LK, Ramiliarisoa O, Le Bras J: In-vitro activity of atovaquone against the African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 1995, 53:381-391.
43. Chiodini PL, Conlon CP, Hutchinson DB, Farquhar JA, Hall AP, Peto Tea, Birley H, Warrell DA: Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. J Antimicrob Chemother 1995, 36:1073-1078.
44. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ: Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996, 54:62-66.
45. Canfield CJ, Pudney M, Gutteridge WE: Interaction of atavaquone with other antimalarials drugs against Plasmodium falciparum in vitro. Exp Parasitol 1995, 80:373-381.
46. Radloff P, Philipps J, Nkeyi M, Hutchinson DB, Kremsner P: Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996, 347:1511-1514.
47. Anderson SL, Ager A, McGreevy PB, Schuster BG, Wesche D, Kuschner R, Ohrt C, Ellis W, Rossan RN, Berman J: Activity of azithromycin as a blood schizontocide against rodent and human plasmodia in vivo. Am J Trop Med Hyg 1995, 52:159-161.
48. Anderson SL, Berman J, Kuschner R, Wesche D, Magill A, Wellde B, Schneider I, Dunne M, Schuster BG: Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann Intern Med 1995, 123:771-773.
49. Sadiq ST, Glasgow KW, Drakeley CJ, Muller O, Greenwood BM, Mabey DCW, Bailey RL: Effects of azithromycin on malariometric indices in the Gambia. Lancet 1995, 346:881-882.
50. Olliaro PL, Trigg PI: Status of antimalarial drugs under development. Bull WHO 1995, 73:565-571.
51. Ringwald P, Bickii J, Basco LK: Randomised trial of pyronardine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet 1996, 347:24-28. This is the first published study of pyronardine outside Chine. In this open trial, chloroquine had a cure rate of 44% and pyronardine 100% at 14 days. The authors suggest that pyronardine could replace chloroquine in Africa.
52. Trape JF, Rogier C: Combating malaria morbidity and mortality by reducing transmission. Parasitol Today 1996, 12:236-240. This is an interesting analysis, supported by epidemiological data of the relationship between transmission, morbidity and mortality from malaria. It suggests that certain interventions may not, in the long term, reduce the overall burden of the disease.